You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 四環醫藥(0460.HK)漲超8% 軒竹生物新藥XZP-5955片獲批臨牀試驗
格隆匯 06-03 10:34
格隆匯6月3日丨四環醫藥(0460.HK)高開高走,現報3.9港元,漲8.64%,暫成交2億港元,最新市值369億港元。四環醫藥今日早間公佈,公司附屬公司軒竹生物科技有限公司自主研發的1類新藥XZP-5955片於2021年5月31日獲得藥物臨牀試驗批准通知書,成為集團2021年1月繼XZP-5610獲得臨牀試驗批准後又一個獲批開展臨牀試驗的創新藥物。四環醫藥昨日午間亦公佈,該集團將於中國地區獨家代理引進韓國東方醫療株式會社(韓國東方醫療會社)旗下的愛拉絲提面部埋植線(線雕)和私密用線兩類產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account